|
A211601
|
A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A companion study to Alliance Study A011502 |
Open (affiliates only) |
|
NRGBR003
|
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or w/o Carboplatin for Node+ or High-Risk Node- Triple-Neg Invasive Breast Cancer |
Open (affiliates only) |
|
S1501
|
S1501: Prospective Evaluation in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III |
Open (affiliates only) |
|
S1703
|
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patient with Metastatic Hormone Receptor Positive Breast Cancer |
Open (affiliates only) |
|
A011202
|
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
Open |
|
A011401
|
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
Open |
|
A011502
|
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As
Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial |
Open |
|
A221505
|
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction |
Open |
|
ADVL1823
|
Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias |
Open |
|
AGCT1531
|
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
Open |
|
AGCT1532
|
A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors |
Open |
|
ALTE15N2
|
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study |
Open |
|
APEC14B1
|
Project: Every Child A Registry, Eligibility Screening, Biology and Outcome Study |
Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621H
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. |
Open |
|
APEC1621I
|
NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes |
Open |
|
APEC1621J
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations |
Open |
|
EA1131
|
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy VS Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoaduvant Chemotherapy |
Open |
|
EA1151
|
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) |
Open |
|
EAI142
|
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer |
Open |
|
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
|
MA39
|
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast cancer |
Open |
|
MDA20160702
|
A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast |
Open |
|
NCI10129
|
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors |
Open |
|
NCI10222
|
A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors |
Open |
|
NRGBR004
|
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer |
Open |
|
RTOG1304
|
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy |
Open |
|
S1418
|
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 cm residual Invasive Cancer or Positive Lymph Node |
Open |
|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
|
UW13061
|
Pilot Study: Comparison of rpFNA and CNB for Breast Tissue Collection for Chemopreventive Studies |
Open |
|
UW14035
|
Correlation of Tumorigenic Properties in Early Stage Breast Cancer: an Investigation of Tumor Types, Mitotic Phenotypes, and Tumor Microenvironment Interactions
|
Open |
|
UW15048
|
Monitoring Microwave Ablation of Breast Tumors Via Real-Time Microwave Imaging |
Open |
|
UW15106
|
Genomic Analysis of Long-Term Survivors with Metastatic Cancer |
Open |
|
UW15114
|
A Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers with Nuclear Epidermal Growth Factor Receptor |
Open |
|
UW16044
|
A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
|
Open |
|
UW16063
|
Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect |
Open |
|
UW16088
|
A randoMized phAse II trIal of fulvestraNt or exemestane wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial) |
Open |
|
UW16106
|
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response |
Open |
|
UW16151
|
Pharmacodynamic biomarkers of standard anti-microtubule drugs as assessed by early tumor biopsy
|
Open |
|
UW17034
|
[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer |
Open |
|
UW17064
|
A Phase II, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
|
Open |
|
UW17107
|
Phase 2 Study of ONC201 with and without Methionine-Restricted Diet in Patients with Metastatic Triple Negative Breast Cancer
|
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW17125
|
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS: A Phase III Prospective Randomized Trial (AFT-25) |
Open |
|
UW17141
|
A Comparison of the Paravertebral Block Versus Pectoralis Block in Controlling Bilateral Post-Mastectomy Pain in Setting of Tissue Expander
|
Open |
|
UW17152
|
An Open-Label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations
|
Open |
|
UW18073
|
Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation |
Open |
|
UW18089
|
A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer |
Open |
|
UW18099
|
A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)
|
Open |
|
UW18101
|
Evaluating the Use of Enhanced Recovery Preoperative Immunonutrition and Carbohydrate Loading Strategies in Immediate Autologous and Alloplastic Breast Reconstruction
|
Open |
|
UW18107
|
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers |
Open |
|
UW18110
|
A Phase I/II Study of OAR-Based, Dose Escalated SBRT with Real Time Adaptive MRI Guidance for Liver Metastases
|
Open |
|
UW18113
|
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
|
Open |
|
UW18133
|
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005) |
Open |
|
UW19004
|
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Open |
|
UW19035
|
An Open-Label Randomized Phase 2 trial of SAR439859, versus Endocrine Monotherapy as per Physician's Choice in Patients with Estrogen Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer with Prior Exposure to Hormonal Therapies |
Open |
|
UW19038
|
Symptom Cluster Experience of Cancer Patient-Caregiver Dyads |
Open |
|
UW19040
|
Engaging Stakeholders to Improve the Quality of Breast Cancer Follow-up: Focus Groups of Survivors and Oncologists |
Open |
|
UW19046
|
A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients with ESR1 Mutations |
Open |
|
UW19056
|
Determining FDG PET/CT Repeatability in Patients with Solid Tumor |
Open |
|
UW19075
|
A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants with Advanced Solid Tumors |
Open |
|
UW19080
|
A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Open |
|
UW19082
|
Symptom Burden, Co-Occurrence, and Trajectories in Children with Advanced Cancer |
Open |
|
UW19092
|
Hormone Replacement Therapy Use by Women at High risk of Breast and Ovarian Cancer after Bilateral Risk-Reducing Salpingo-Oophorectomy
|
Open |
|
UW19115
|
Engaging Stakeholders to Improve the Quality of Breast Cancer Follow-up: a Pilot Study to Assess Survivors Symptoms and Concerns |
Open |
|
UW19136
|
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) |
Open |
|
UW19140
|
A Phase 1b/2, Open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors |
Open |
|
UW20000
|
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) |
Open |
|
UW20046
|
A Phase 2 Study of Futibatinib in Patients with Specific FGFR Aberrations |
Open |
UW Carbone